In conclusion, CASP8 can be used as a potential biomarker for prostate cancer and provide an effective prognosticator for the risk grade of BCR in prostate cancer, facilitating early-stage personalized treatment and improving prognosis. Here, CASP8 is linked to prostate carcinoma.